anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current study aims to test the effectiveness of computer-based interpretation bias modification training as a therapeutic intervention for social anxiety disorder (SAD). Individuals who experience social anxiety often have difficulty in engaging in social situations, such as speaking in front of a group and maintaining a conversation. For youngsters, this may take the form of avoidance, including avoiding situations such as raising one's hand in class, eating in front of other people and participating in small group activities. Additionally, those with social anxiety are more likely to interpret ambiguous social scenarios in a threatening way than are control subjects (Bogels, Snieder, \& Kindt, 2003; Miers, Blote, Bogels, \& Westenberg, 2008; Vassilopoulos \& Banerjee, 2008; Vassilopoulos, 2006; Muris, Meckelbach, \& Damsma, 2000). Research has shown that interpretation biases are modifiable at a young age (Muris, Huijding, Mayer, \& Hameetman, 2008; Vassilopoulous, Bangerjee, Prantzalou, 2009; Muris, Huijding, Mayer, Remmerswaal, \& Vreden, 2009; Lothmann, Holmes, Chan, \& Lau, 2010).

Participants between the ages of 8-12 years old, with social anxiety, will be randomly assigned to one of three treatment conditions: two conditions are designed to manipulate the interpretation bias or a wait-list control condition. All study procedures will be conducted online. Subjects do not need to come to the University of Wisconsin-Milwaukee to participate. Thirty children with social anxiety will be randomly assigned to one of the three conditions, and will be assessed at baseline, post-treatment, and 1-month follow-up. The waitlisted participants will also be invited to undergo the training program after the 1-month follow-up assessment is completed. This study is expected to generate important data that will guide the development of an accessible, cost-efficient, and effective cognitive intervention for individuals suffering from social anxiety.
The nematophagous fungus Hyalorbilia oviparasitica and relatives (Hyalorbilia spp.) are known to parasitize several endoparasitic nematodes. In this project, we hypothesized that indigenous populations of this fungus could be used to predict nematode suppression in agricultural field soils. We quantified Hyalorbilia spp. in soil samples from 44 different sugar beet fields in the Imperial Valley of California. Seven soils harboring Hyalorbilia spp. and two that tested negative for the fungi were examined for nematode suppressive activity. Untreated and autoclaved portions of each soil were planted with cabbage and infested with sugar beet cyst nematode (Heterodera schachtii) juveniles. Females and cysts of H. schachtii were enumerated after 12 weeks. In the seven soils harboring Hyalorbilia spp., females and cysts in the untreated soils were reduced by 61 to 82% compared with the autoclaved controls. Soils with no detectable Hyalorbilia spp. exhibited no nematode suppression. Two novel Hyalorbilia strains, HsImV25 and HsImV27, were isolated from H. schachtii females reared in field soil using an enrichment and double-baiting cultivation technique. Both strains suppressed H. schachtii populations by more than 80% in soil-based assays, confirming that Hyalorbilia spp. are the likely causal agents of the nematode suppression in these soils. This study demonstrated that indigenous populations of a hyperparasite (Hyalorbilia spp.) in agricultural field soils predicted suppressive activity against a soilborne plant pathogen (H. schachtii). To our knowledge, this is the first report to demonstrate this capability. We anticipate that this research will provide a blueprint for other similar studies, thereby advancing the field of soilborne biological control.
AIM: The aim of this study was to investigate whether multimodal analgesia can decrease postoperative opioid usage in patients undergoing shoulder arthroscopy.
METHODS: Patients diagnosed with subacromial impingement syndrome who underwent acromioplasty at our institution between October 2022 and November 2023 were retrospectively analyzed. Patients were divided into an observation group and a control group based on postoperative pain management methods. The control group received intravenous self-controlled electronic analgesia (sufentanil injection 1 μg/kg + butorphanol injection 4 mg + 0.9% NaCl injection to 100 mL), while the observation group received multimodal analgesia (ropivacaine subacromial pump 3 mL/h, combined with oral celecoxib and acetaminophen). Visual Analog Scale (VAS) scores were recorded preoperatively and at various postoperative time points, and opioid usage, length of hospital stay, and analgesia-related complications within 1 week postoperatively were compared between groups. The 36-item Short Form Health Survey (SF-36) scores and the Constant-Murley score (CMS), were also assessed 1 day and 1 week after treatment.
RESULTS: One hundred thirty-two patients were included in the study, 66 in the observation group and 66 in the control group. In the control group, there were 46 males and 20 females, with a mean age of 55.47 ± 11.42 years and in the observation group 44 males and 22 females, with a mean age of 56.13 ± 12.19 years The observation group consistently reported significantly lower pain intensity compared to the control group at 8 h (T1), 24 (T2), and 48 h (T3) after surgery (p < 0.05). Additionally, the observation group exhibited significantly lower opioid usage and complication rates compared to the control group (p < 0.05). SF-36 scores and CMS scores were significantly higher in the observation group 1 week after treatment compared to the control group (p < 0.05).
CONCLUSIONS: Following shoulder arthroscopy, multimodal analgesia effectively reduces opioid consumption, lowers complication rates, and provides effective short-term pain relief. This approach carries significant implications for improving patient outcomes.
Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
The invention provides a miRNA marker, which is miR-4443. The invention utilizes NCBI GEO data to search out a breast cancer minRA data set and a breast cancer mRNA data set which meet the requirements, analyzes the data sets and screens miRNA-miR-4443 closely related to breast cancer. miR-4443 can be used for judging the risk of breast cancer. Tests prove that miR-4443 can effectively distinguish a breast cancer sample from a normal sample. On the basis, miR-4443 can also be used for preparing a medicament for inhibiting breast cancer proliferation or invasion. The invention provides a new idea for the molecular mechanism research of breast cancer, provides a new diagnosis method for clinically diagnosing breast cancer occurrence and metastasis on a molecular level, and provides a new drug target for breast cancer treatment.
The invention discloses a puffed food made with lotus root skin. Raw materials are added with water to be stirred into wet stock, which then goes through preparation processes of puffing, cutting into particles, cooling and conveying, rolling and pressing, baking, etc.; a seasoning agent is added in one of the preparation processes so as to obtain finished products with definite shape and flavor. The raw materials comprise grain powder and also lotus root skin powder which can pass through a 60-mesh screen and have the water content no more than 10 percent. The weight ratio of the grain powder and the lotus root skin powder is between 1:0.3 to 1: 2.5 and the water content of the wet stock ranges from 20 to 25 percent, while the added content of the seasoning agent accounts for 5 percent to 10 percent of the total weight of the puffed food and the water content of the finished product ranges from 3 to 6 percent. The puffed food of the invention has the health-care functions of clearing away dysphoria, quenching thirst, arresting seminal emission, promoting blood, eliminating nocturnal emission, adjusting chills and fever, curing splenic diarrhea, protracted dysentery, nursing intestines and stomach, etc., and is the best nutrient for people who have a lingering illness, women after the birth or the old and the weak, thus being an ideal heath-care leisure food.
An antivirus agent is obtained by maintaining a solution of oxytetracycline under mildly alkaline conditions until substantial antivirus activity (test micro-organism influenza virus) is imparted to the solution.  The solvent may be water, a water-miscible organic solvent, e.g. alcohol or a mixture thereof.  A pH of 10 to 12 and a temperature of 20 DEG  to 100 DEG  C. is preferred.  The higher the temperature, the shorter the digestion time.  Thus at 20 DEG  to 35 DEG  C. the time is 2 to 10 days; at 90 DEG  to 100 DEG  C. the time is 1/2 to 3 hours.  The lower temperature produces the most active product.  The agent may be isolated from the solution by (a) freezy-drying or (b) acidifying to pH 2 to 4 and filtering off the separated solid.  The original solution may be rendered alkaline by an organic or inorganic base, the alkali metal hydroxides being preferred.  Any strong acid may be used in step (b); preferred are phosphoric, sulphuric or hydrochloric. The antivirus agent is active against the influenza A virus; has low solubility in dilute, aqueous acid; the acid form is soluble in acetone, methanol, butanol and pyridine, but insoluble in ether, chloroform, dioxane and acetonitrile; its activity against Klebsiella pneumoniae is preferably less than 10 per cent of that of oxytetracycline.  The agent may be used therapeutically with other antibiotics (see Group VI).ALSO:A therapeutic preparation comprises a solution of an antivirus agent obtained by maintaining oxytetracycline under mildly alkaline conditions until substantial activity against the influenza A virus is obtained (see Group IV (b)].  Optional additions are penicillin, streptomycin, "Viomycin" (R.T.M.) or oxytetracyline.
The health and well being of military personnel, and consequently the capacity for optimal functioning of military units, are compromised by posttraumatic stress disorder (PTSD). PTSD is associated with high personal and societal costs. Post-deployment rates of PTSD range from 5-20%; approximately 8% of combat exposed military personnel develop new onsets of PTSD. PTSD is frequently comorbid with other psychiatric disorders. Untreated PTSD is associated with high rates of suicide, medical services utilization, relationship impairment, legal difficulties, decreased worker productivity, and decreased military readiness.

While PTSD treatment can be effective, individuals with PTSD may not seek treatment. Drop out and medication noncompliance are common. Moreover, military personnel encounter both real and perceived barriers to seeking treatment. Given the availability of effective treatments contrasted with the low rates of military personnel who present and complete treatment, figuring out how to connect individuals with PTSD symptoms into treatment and then helping them to stay engaged is a high priority. Motivational enhancement therapy (MET) has shown promise in promoting treatment entry and enhancing both retention and successful outcomes. A brief, telephone-delivered MET called a "check-up," has shown promise in promoting self-initiated behavior change as well as voluntary treatment entry, enhanced retention, and more successful outcomes for substance abuse. Despite these promising findings, no work has focused on adapting MET for enhancing self-referral and treatment seeking with individuals with PTSD who are active duty and who are not already in treatment. Active duty military face additional challenges to entering treatment than veterans and thus specific research is necessary to evaluate whether similar programs would be efficacious for active duty personnel.

Adapting the "check-up" application with military personnel is warranted for three key reasons: (1) it has the potential of overcoming barriers to treatment-seeking, i.e., stigma and apprehension of a negative impact on one's military career; (2) it has the potential of attracting voluntary participation; and (3) protocols for disseminating this low cost intervention for use with deployed military can readily be developed and evaluated.
Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
Buprenorphine in intravenous (2mg, 4mg, 8mg, 12mg and 16 mg) and sublingual (12mg) doses has been administered to non-dependent subjects to examine cardiovascular, respiratory and subjective effects at doses comparable to those used for treatment of opioid dependence. Compared with placebo, there were no statistically significant differences among any of the treatment conditions for blood pressure, heart rate, respiratory rate, O2 saturation or skin temperature across time. Systolic BP was higher in the 8 mg group than placebo (3 hour AUC values). Minimum and maximum effects were similar across all treatments. Subjects remained responsive to low voice and responded to computer prompts. Some subjects showed irritability, but no other changes were observed.

The respiratory effects of sublingual buprenorphine were compared with the effects of methadone in a double-blind, parallel group, dose ranging comparison of single doses of buprenorphine sublingual solution (1, 2, 4, 8, 16, or 32 mg) and oral methadone (15, 30, 45, or 60 mg) in non-dependent, opioid-experienced volunteers. In this study, hypoventilation not requiring medical intervention was reported more frequently after buprenorphine doses of 4 mg and higher than after methadone. Both drugs decreased O2 saturation to the same degree.
This pilot study is a randomized controlled study of 20-30 individuals with Parkinson's disease will have a control group with no training and a research group with yoga training. The control group will have the opportunity to attend yoga training of the same intensity after the study is completed. The effects of yoga will not be on the control group. Data on physical function will be derived from assessments including strength, balance, flexibility, ROM. gait, posture and functional analysis performed in the Georgia Holland Cardiopulmonary and Neuromuscular Research Lab. Questionnaires related to quality of life, depression and falls will determine psychological impact or yoga training. Vital signs, pulmonary function tests and blood draws will be done in the General Clinical research Center (GCRC) and protein analysis will be done in the diabetes research lab.
Training: Participants will complete three training bouts in a session. For these training bouts, participants will be instructed to walk around the perimeter of the 9m x 15m laboratory while wearing the custom gait biofeedback device and visual display glasses. The training bouts will each be 6 minutes in duration with a 5-minute break in between bouts. The biofeedback will be intermittent, with one minute on and one minute off, in order for the individual to not become dependent on the feedback and to promote motor learning. Participants will be told that the device measures the angle their paretic leg is at, and as they move their leg, the line on the screen will move. They will be shown as they move their leg farther back, the line moves up, closer to the target. Participants will not be given specific feedback on what walking strategies to use to increase hip extension angle. If the participant surpasses the target hip extension angle, the target will blink green.
A no-base type, aqueous alkali-based hair-straightening composition having a pH between 12 and about 14 initiates and enhances the permanent hair-straightening effect. The hair-straightening composition comprises, as an active hair-straightening agent, a strong alkali, and a water-soluble hair-straightening initiating agent. The initiating agent is a mercapto (C 4  -C 6 ) dicarboxylic acid having a sulfhydryl functional group on a carbon atom alpha to one or both of the carboxy acid groups, salt thereof or derivative thereof, and is a hair keratin-disulfide reducing agent. The initiated composition particularly augments and enhances the permanent hair-straightening benefits of sodium hydroxide, yet substantially overcomes negative hair conditioning problems normally associated therewith. Thiomalic acid and 2,5-dimercaptoadipic acid are preferred initiating agents. Also disclosed is a hair-straightening system and method for straightening hair with the foregoing compositions.
Microorganisms are provided, such as lactic acid bacteria ( e.g. ,  Lactococcus lactis ) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a CeD-specific antigen ( e.g. , a gliadin polypeptide comprising at least one HLA-DQ2 specific epitope, at least one deamidated HLA-DQ2 specific epitope, at least one HLA-DQ8 specific epitope, at least one deamidated HLA-DQ8 specific epitope, or a combination of (a) at least one HLA-DQ2-specific epitope and/or at least one deamidated HLA-DQ2 specific epitope, and (b) at least one HLA-DQ8 specific epitope and/or at least one deamidated HLA-DQ8 specific epitope) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. Compositions ( e.g. , pharmaceutical compositions), methods of using the microorganisms and compositions are provided,  e.g. , for the treatment of celiac disease (CeD). The microorganism may be administered orally, delivering the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides.
Techniques and examples pertaining to evaluating the health condition of a patient based on a diagnostic aspect of the patient are described. A method for evaluating the health condition may involve obtaining a measurement value of the diagnostic aspect of the patient by a diagnostics measurement device. The method may also involve calculating a relative ratio by a processor communicatively coupled to the diagnostics measurement device. The processor may calculate the relative ratio by dividing the measurement value by a standard average value of the diagnostic aspect. The method may also involve the processor calculating a health deviation by subtracting a baseline value from the relative ratio. The method may also involve the processor designating a health indicator based on the health deviation, such that the health indicator serves as an indication of the health condition of the patient.
PURPOSE: To compare eye tracking and Teller acuity cards (TAC) for assessment of visual acuity in children with cortical, or cerebral, visual impairment (CVI).
DESIGN: Reliability and validity study.
METHODS: We recruited 41 children with CVI from a single academic pediatric neuro-ophthalmology clinic. All children performed eye tracking to measure visual acuity, and 26 children completed TAC assessment by a masked examiner. Additionally, 2 pediatric neuro-ophthalmologists graded visual behavior using the 6-level Visual Behavior Scale (VBS). Eye tracking and TAC were performed at baseline and at 1 month. Test-retest reliability of eye tracking and TAC were assessed using the intraclass correlation coefficient (ICC). Eye tracking and TAC visual acuities were correlated with one another and VBS scores using the Spearman correlation coefficient.
RESULTS: Test-retest reliability was excellent for eye tracking measurement of visual acuity (ICC = 0.81, P < .0001). For pediatric CVI, TAC test-retest reliability was fair (ICC = 0.42, P = .04). There was a moderate correlation between eye tracking and TAC (r = 0.43, P = .03) and between TAC and VBS score (r = 0.50, P = .009), and a strong correlation between eye tracking grating acuity and VBS score (r = 0.72, P < .0001).
CONCLUSIONS: In our cohort of children with CVI, grating acuity measured by eye tracking demonstrated higher test-retest reliability and stronger correlation with pediatric neuro-ophthalmologic assessment of visual behavior than Teller acuity. Objective determination of gaze direction by an eye tracking camera may be more accurate than human assessment in this population. Future research is needed to determine the optimal methods of longitudinal assessment of visual function and functional vision in children with CVI.
Patients receive copanlisib IV over 1 hour on days 1, 8 and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. Patients who achieve at least a partial response (MRD-positive) continue on treatment for 2 additional cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 7, patients receive copanlisib IV over 1 hour on days 1 and 15 for an additional 6 cycles in the absence of disease progression or unacceptable toxicity.
The number of patients with multiple comorbidities is significantly growing. Medical advances have made it possible to perform challenging surgical interventions to increase life expectancy. Yet, it is this group of patients that has a high risk of complications after a surgical intervention leading to a reduction in their quality of life and self-sustainability. Current European and Dutch guidelines recommend the implementation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients. However, the evidence underlying the guideline recommendations is scarce. Furthermore, the implementation process of a well-functioning MDT meeting can be a challenge and may sometimes lead to no MDT meeting at all. And finally, the guidelines do not specify conditions by who or how the MDT meeting should be done, for example required attending specialties or specific subjects to be discussed. A broad practice variation in preoperative MDT meetings might thus be present and could be a complicating factor in the equal treatment of patients compliant to 'best practice'. The current survey will evaluate practice variation of preoperative MDT meetings for high risk noncardiac surgical patients in the Netherlands and assess possible facilitators and barriers in the implementation process.
Beta-adrenergic blocking propanolamine derivs. Title cpds. of formula (I) (where R' is carboxyamido (pref. acetamido), lower alkoxycarbonylamino or carbamoyl which can be separated from the phenyl ring by a methylene or ethylene groups; R2 and R3 are H or lower alkyl; R4 is carboxyamido, sulphonamido, lower alkoxycarbonyl: amino, carbamoyl or sulphamoyl which can be separated from the phenyl ring by a methylene or ethylene group; R5 is H, lower alkyl, lower alkanoyl or benzyl, X is O or S; Y is O, S, SO, SO2, NH or a direct bond; n is 1,2 or when Y is a direct bond, also O or 4; and rings A and B may be further substd. by one or more halogen atoms or lower alkyl, alkenyl, alkoxy or alkenoxy groups) and their pharmaceutically tolerable acid addition salts, as well as aldehyde condensation products of (I; R5 = H) and esters in which the 2-hydroxy group is esterified with a lower alkane carboxylic acid. Their beta-adrenergic blocking effect is stronger on cardiac than on peripheral receptors and they are useful for heating e.g. angina pectoris and cardiac arrhythmias.